Verily, Alphabet's life sciences division, is discontinuing its medical device program and reducing staff as part of a strategic shift. CEO Stephen Gillett communicated this decision in an internal memo, highlighting the company's legacy of developing innovative medical devices. However, he emphasised the necessity for difficult choices as Verily redirects its focus towards artificial intelligence (AI) and data infrastructure.
This move aligns with Alphabet's broader strategy of aggressively investing in AI while streamlining operations. Verily's device program encompassed various projects, including a clinical study watch, retinal camera, and a partnership with Dexcom for wearable glucose sensors. The company aims to concentrate on applying AI and data science to accelerate learning and improve healthcare outcomes.
Verily has been strategically refocusing since 2023, streamlining its business to achieve sustained commercial success. This shift involves consolidating leadership and prioritising precision health initiatives. The company will now operate as a centralised product organisation, leveraging its strengths in AI and data science to bridge the gap between research and care.
